Back to mobile site

Morning Movers 09/26: (MELA) (ZN) (ES) (OMEX) Higher; (EK) (SINA) (IVN) Lower

September 26, 2011 10:14 AM EDT
MELA Sciences (Nasdaq: MELA) 72% HIGHER; reports the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for the MelaFind Pre-Market Approval (PMA) application. Click here to see the full report.

Eastman Kodak Co. (NYSE: EK) 22.9% LOWER; in an 8-K filing after the close Friday, Eastman Kodak said it initiated a draw of $160 million under the Second Amended and Restated Credit Agreement, dated as of April 26, 2011, for general corporate purposes.

Zion Oil & Gas (Nasdaq: ZN) 16.8% HIGHER; continuing to bounce following a 44 percent decline since the beginning of September. Volume looks heavy.

EnergySolutions (NYSE: ES) 11.6% HIGHER; stock holding over key technical levels after pushing above $3 on Thursday of last week. Including today's move higher, the stock is up about 30 percent in three trading sessions.

Ivanhoe Mines (NYSE: IVN) 11.5% LOWER; said in a statement today that the investment agreement for the Oyu Tolgoi Project remains a fair and legally binding contract that deserves and requires the unqualified support of all parties.

SINA (Nasdaq: SINA) 10.9% LOWER; stock plunging after technicians pushed the stock below the all-important 200-day moving average just after the open. Volume seems heavy.

Odyssey Marine Exploration, Inc. (Nasdaq: OMEX) 9.8% HIGHER; announced today that it has confirmed the identity and location of the shipwreck site of the SS Gairsoppa nearly 4,700 meters below the surface of the North Atlantic, approximately 300 miles off the coast of Ireland in international waters.

Delcath Systems (NASDAQ: DCTH) 9.7% HIGHER; announced that James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine, presented a poster Sunday that includes additional data from the metastatic neuroendocrine tumor (mNET) cohort of Delcath's recently completed Phase 2 clinical trial of its chemosaturation system. In this mNET cohort, 24 patients with unresectable mNET in the liver underwent an average of three chemosaturation procedures with concentrated melphalan and subsequent extra-corporeal venous hemofiltration. Dr. Pingpank will also present the updated hepatic response rate of 70% in 20 evaluable patients, and median overall survival of 30.4 months in all 24 patients on an intent-to-treat basis.

American Eagle Outfitters, Inc. (NYSE: AEO) 8% HIGHER; after the close Friday, Chairman Jay Schottenstein disclosed the purchase of 1,000,000 shares from 9/21-9/22 at prices from $11.06-$11.28. The purchased brings his stake to 5,285,258 indrect (by SEI, Inc.). He also owns 688,653 direct, 5,771,205 by Trusts and 500,000 by LLP.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Jay L. Schottenstein, Morning Movers